CDK4/6-Inhibitors Versus Chemotherapy in Advanced HR+/HER2-Negative Breast Cancer: Results and Correlative Biomarker Analyses of the KENDO Randomized Phase II Trial.

Another limitation is that being the study underpowered, most of the analyses carried out did not reach statistical significance, hence only apparently relevant numerical trends could be discussed in most cases, making our results essentially hypothesis-generating.

also in 111,027 other papers